Table 2.
Type and methodology of PP studies identified in the SLR.
| First author (year) | Region/country | MPLC phases in which applications were identified | Methods used | Disease area | Attribute | References | |
|---|---|---|---|---|---|---|---|
| Qualitative | Quantitative | ||||||
| Vennedey et al. (2018) | Europe (Germany) | HTA, Reimbursement | - | DCE | Periodontal disease | Cost, Convenience, QoL | (11) |
| Holmes et al. (2018) | Europe (UK) | BRA | - | DCE | Epilepsy | Efficacy, Safety, QoL | (21) |
| Fifer et al. (2018) | Australia | HTA, Pricing/Reimbursement | - | DCE | Diabetes | Efficacy, Safety, Cost, Convenience | (20) |
| Postmus et al. (2018) | Europe (UK) | BRA | - | DCE | Multiple myeloma | Efficacy, Safety | (22) |
| Milovanovic et al. (2017) | Europe (Italy) | HTA | Survey/Questionnaire | - | Anemia/inflammatory bowel disease | Efficacy, Safety Convenience | (23) |
| Von Arx et al. (2016) | Europe (Denmark) | BRA | - | DCE | Diabetes | Efficacy, Safety | (24) |
| Eliasson et al. (2017) | Europe (France, Germany, UK) | BRA | - | DCE | Oncology | Efficacy, Safety, Convenience, QoL | (25) |
| Eliasson et al. (2017) | Europe (UK) | BRA, HTA | - | DCE | Psoriasis | Efficacy, Safety, Cost, Convenience | (26) |
| Muhlbacher et al. (2017) | Europe (Germany) | HTA | - | DCE | Hepatitis C | Efficacy, Safety, Cost, Convenience | (27) |
| Janssen et al. (2016) | Europe (Germany) | HTA | - | VAS | Kidney diseases | Efficacy, Safety, Convenience, QoL | (16) |
| Hollin et al. (2016) | USA | BRA | - | BWS | Duchene muscular dystrophy | Efficacy, Safety, QoL | (28) |
| Hollin et al. (2017) | USA | BRA | - | BWS + DCE | Duchene muscular dystrophy | Efficacy, Safety, Convenience | (29) |
| Morel et al. (2016) | Europe (UK) | BRA | - | DCE | Rare diseases | Efficacy, Safety, Convenience, QoL | (14) |
| Hauber et al. (2016) | USA | BRA | - | DCE | Eczema | Efficacy, Safety | (30) |
| Janssen et al. (2016) | USA | BRA, Pricing | - | BWS + DCE | Diabetes | Efficacy, Safety, Cost, Convenience | (31) |
| Muhlbacher et al. (2016) | Europe (Germany) | HTA | - | DCE | Hepatitis C | Efficacy, Safety, Convenience | (32) |
| Postmus et al. (2015) | Europe | BRA | - | MCDA | Oncology | Efficacy, Safety | (33) |
| Roy et al. (2015) | USA | HTA, Pricing | - | DCE | Insomnia | Efficacy, Safety, Cost, Convenience | (34) |
| Ho et al. (2015) | USA | BRA | - | DCE | Obesity | Efficacy, Safety, Convenience | (35) |
| Mol et al. (2014) | Europe (Netherlands) | BRA | - | DCE | Diabetes | Efficacy, Safety | (36) |
| Peay et al. (2014) | USA | BRA | - | BWS | Duchene muscular dystrophy | Efficacy, Safety | (37) |
| Danner et al. (2011) | Europe (Germany) | HTA | - | AHP | Depression | Efficacy, Safety, QoL | (8) |
| Johnson et al. (2010) | USA | BRA | - | DCE | Irritable bowel syndrome | Efficacy, Safety | (38) |
| Aristides et al. (2004) | Europe (France, Germany, Italy, Spain, UK) | HTA, Pricing/Reimbursement | - | DCE | Diabetes | Efficacy, Safety, Cost, Convenience | (39) |
| Sorum (1999) | US | Pricing | - | Rating scale + SG | ORL/infection | Efficacy, Safety, Cost | (19) |
BRA, benefit–risk assessment; HTA, health technology assessment; MPLC, medicinal product life cycle; DCE, discrete choice experiment; VAS, visual analog scale; BWS, best–worst scaling; AHP, analytic hierarchy process; SG, standard gamble; MCDA, multicriteria decision analysis; QoL, quality of life.